bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 849: Detection of circulating micrometastasis in pancreatic cancer patients by immunomagnetic nanoparticles combined with RT-PCR
Authors: Zhou Jiahua , Hu Liang , Yu Zeqian , Zheng Jie , Yang Detong , Bouvet Michael , Hoffman Robert M. 
Published: February 2011

Abstract
By the time patients are diagnosed with pancreatic cancer, circulating cancer cells probably exist. Therefore, the detection of pancreatic tumor cells in the peripheral circulation could be used to diagnose early pancreatic cancer, which would otherwise not be detected by current imaging methods. The expression levels of h-TERT, CK20, CEA, and c-met were detected in a model of circulating micrometastasis in pancreatic cancer. The sensitivity and specificity of the measurements were evaluated. The expression of the above genes was subsequently measured in the circulation of pancreatic cancer patients. We compared their expression rate in pancreatic cancer patients at different stages to screen for the indicator with highest sensitivity and specificity in the detection of circulating pancreatic cancer cells. Immunomagnetic nanoparticles combined with RT-PCR enabled the detection of one tumor cell per 1×107 peripheral blood mononuclear cells. The positive expression rates of c-met, h-TERT, CK20, and CEA in the pancreatic cancer group were 80% (20/25), 100% (25/25), 84% (21/25), and 80% (20/25), respectively, while in the benign disease control group the rates were 0% (0/15), 0% (0/15), 6.77% (1/15), and 0% (0/15), respectively. There was a significant difference in the positive expression rate between the two groups (P&lt;0.05). The specificity of h-TERT, CEA, and c-met was higher than that of CK20. The positive expression rate of the four genes was not related to gender, age, tumor size, CA-199 or CEA serum levels (P&gt;0.05). However, the positive expression of c-met, CK20, and CE closely correlated with tumor stage (P&lt;0.05). Immunomagnetic nanoparticles combined with RT-PCR were specific and sensitive for the detection of micrometastasis. The positive expression of c-met, h-TERT, CK20, and CEA in the circulation of pancreatic patients could be used as an indicator for circulating cancer cells. The detection rate of circulating cancer cells increased to 100% by the combined measurement of the four genes, suggesting the clinical utility of this approach.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 849.
Abstract 850: 32H2, a new diagnostic tool for HER2 CTFs
Authors: Palau Josep L. Parra , Peg Vicente , Escorihuela Marta , Mancilla Sandra , Arribas Joaquín 
Published: February 2011

Abstract
The tyrosine kinase receptor HER2 belongs to the Epidermal Growth Factor Receptor (EGFR) family and is amplified in 30% of breast cancer patients. These patients are currently treated with Herceptin (Trastuzumab), a monoclonal antibody against the extracellular domain of HER2.
A group of HER2 positive patients express a series of carboxy terminal fragments (CTFs) of the receptor. These patients have worse prognosis and are more likely to develop metastasis. In addition, CTFs positive patients are resistant to treatment with Herceptin.
Functional characterization of the different CTFs shows that only those containing the transmembrane domain are active. Furthermore, the CTF generated by alternative initiation of translation at Methionine 611, CTF-611, seems to be a hyperactive due to its ability to constitutively form dimers maintained by disulfide bonds. These hyperactive dimers specifically control the expression of genes causally involved in malignant transformation, providing a likely mechanism for the clinical observations made in patients expressing CTFs.
To date, the presence of CTFs in breast tumors have been studied by Western blot or by double immunoflourescence, using two antibodies, one targeting the intracellular domain and the other the extracellular domain of the receptor. However, both techniques are not able to distinguish between active and inactive CTFs. In addition, only careful comparison of the electrophoretic migration of the species found in tumor samples with those expressed in cell lines transfected with individual CTFs allows the identification of individual CTF. Obviously these techniques cannot be used to effectively determine the presence of active CTFs in large-scale clinical studies. Furthermore, given its hyperactivity, it would be useful to have a specific antibody against 611-CTF.
Here we present the generation and characterization of a monoclonal antibody that recognize specifically 611-CTFs. The low affinity of the antibody for the full-length HER2 may be explained by structural features of the antibody epitope. Using the antibody in a collection of paraffin embedded tumors, we were able to identify a subgroup in the HER2 positive tumors with worst clinical outcome.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 850.
Abstract 853: Prognostic significance of VEGF mRNA in pN0 patients with colorectal cancer
Authors: Wong SC Cesar , Lam Money YY , Ma Brigette BY , Au Thomas CC , Chan Charles ML , Hui Edwin P , Chan John KC , Chan Anthony TC 
Published: February 2011

Abstract
Objectives:
Recently, we discovered isolated cytokeratin 20 (CK20) positive cells in pN0 lymph nodes (LN) from patients with colorectal cancer (CRC) and molecular dissection of this micrometastasis pathway is essential for us to understand which metastasis-related mRNA genes are involved. Using tumor metastasis quantitative polymerase chain reaction (QPCR) arrays, vascular endothelial growth factor (VEGF) mRNA has the highest median fold change in CK20 positive pN0 LN when compared to CK20 negative pN0 LN from patients with CRC (AACR Infection and Cancer abstract number B47). In this study, we validate the QPCR array results by measuring VEGF mRNA concentration in an independent set of pN0 patients with CRC and examine the prognostic significance of VEGF mRNA in the same cohort of patients.
Materials and Methods:
Twenty-nine paraffin-embedded pN0 LN specimens with CK20 positive cells and the same number of specimens without CK20 positive cells from patients with CRC detected by immunostaining were retrospectively retrieved from the Department of Pathology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region. Total RNA was extracted from each sample for the quantification of VEGF mRNA using primers and a Taqman minor groove binder probe which labeled with a carboxyfluorescein reporter dye at the 5′-end and a nonfluorescent quencher at the 3′-end (Applied Biosystems, Foster City, USA). All 58 pN0 patients with CRC were follow-up for 48 months from their respective diagnosis for recurrent or metastatic CRC and a recurrent/metastatic curve was plotted using the median copy number of VEGF mRNA as the cut-off point.
Results:
The median concentration of VEGF mRNA in CK20 positive pN0 LN (35710 copy numbers, range: 5189-51240 copy numbers) was significantly higher than those in CK20 negative pN0 LN (1654 copy numbers, range: 210-4450 copy numbers) (p &lt; 0.0001, Mann Whitney test). Using the median VEGF mRNA copy number (35710) of 29 CK20 positive pN0 patients with CRC as the cut-off point to plot the recurrent/metastatic curves, the time to recurrence or metastasis was significantly shorter for 14 patients with VEGF mRNA concentration &gt; 35710 copy numbers (median recurrence/metastasis = 29.5 months) than for 15 patients with VEGF mRNA concentration ≤ 35710 copy numbers (p &lt; 0.05, log-rank test).
Conclusions:
VEGF mRNA concentration is significantly correlated to the time of recurrence/metastasis and it may be able to predict the risk of recurrence/metastasis in pN0 patients with CRC.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 853.
Abstract 854: Claudin-5 expression in tumor cells is a potential prognostic marker in pediatric ependymoma
Authors: Virág József , Baksa Gábor , Schaff Zsuzsa , Tímár József , Garami Miklós , Hegedũs Balázs 
Published: February 2011

Abstract
Ependymomas are common pediatric brain tumors that originate from the ependymal cell layer and characterized by poor prognosis due to frequent recurrence. However, the current WHO grading system fails to accurately predict clinical behavior. In a retrospective study, we performed the immunohistochemical analysis of 35 pediatric ependymomas for critical components of the cell-cell junctions including cadherins, claudins and occludins. Surprisingly, we found that a number of supratentorial but not infratentorial ependymoma expressed high levels of the brain endothelial cell tight junction component claudin-5 in tumor cells. Interestingly, this region specific expression pattern was also found in the choroid plexus epithelium of the lateral ventricles from tumor free neonatal tissue samples. Ultrastructural studies of human ependyma from various brain regions confimed that the observed protein expression pattern results in distinct regional differences in cell-cell junction organization and thus in ependymal barrier function. Nevertheless, we observed a significant increase in overall survival in patients bearing claudin-5 expressing ependymoma cells. These findings might - at least in part - be explained by the high expression cell-cell junction proteins that can interfere with the invasive capacity of tumor cells. Our data indicates that the assessment of claudin-5 expression in ependymoma cells is a potentially useful prognostic marker in this pediatric CNS malignancy.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 854.
Abstract 855: Medication use and ovary cancer risk in the California Teachers Study
Authors: Duan Lei , Lacey James , Clarke-Dur Christina , West Dee , Bernstein Leslie , Henderson Katherine 
Published: February 2011

Abstract
Background: Approximately 21,000 new cases of ovarian cancer are diagnosed in the United States each year. Because inflammation is thought to affect ovarian carcinogenesis, non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin and ibuprofen, and other medications such as acetaminophen and histamine receptor antagonists, may affect the risk of ovarian cancer. However, existing epidemiological evidence on these associations is mixed.
Methods: We assessed the relationship between medication use and risk of invasive epithelial ovarian cancer in the California Teachers Study (CTS), a prospective cohort of former or current female public school teachers and administrators in California. Analysis included 104,184 women, of whom 420 were diagnosed with invasive epithelial ovarian cancer during follow-up through December 31, 2007. Self-reported medication use from the baseline CTS questionnaire (1995-1996) was used to classify exposures. Relative risks (RR) and 95% confidence intervals (CI) were obtained using Cox proportional hazards methods.
Results: Regular use, defined as at least once a week, of aspirin (RR 0.96; 95%CI 0.76 − 1.19), non-aspirin NSAIDs (RR 1.04; 95%CI 0.80 − 1.30), acetaminophen (RR 1.13; 95%CI 0.85 − 1.50) or histamine receptor antagonists (RR 0.85; 95%CI 0.58 − 1.20) was not associated with ovarian cancer risk. Ovarian cancer risk was not associated with daily use of aspirin (RR 1.04; 95%CI 0.77 − 1.45) or non-aspirin NSAIDs (RR 0.85; 95%CI 0.56 − 1.31) but was associated with daily use of acetaminophen (RR 1.82, 95%CI 1.01 − 2.95), and the latter association persisted after excluding ovarian cancers diagnosed during the first one to five years of follow-up. Two-thirds of the daily acetaminophen users also reported using acetaminophen for more than three years, but there was no association between increasing duration of use and ovarian cancer risk.
Conclusion: Our results do not support the hypothesis that these medications reduce the risk of ovarian cancer. Conversely, the finding that daily acetaminophen use was associated with increased risk of ovarian cancer differs from previous studies and may warrant further investigation.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 855.
Abstract 860: Hypertension, diuretics, and antihypertensives in relation to bladder cancer
Authors: Jiang Xuejuan , Castelao J. Esteban , Yuan Jian-Min , Groshen Susan , Stern Mariana C. , Conti David V. , Cortessis Victoria K. , Coetzee Gerhard A. , Pike Malcolm C. , Gago-Dominguez Manuela 
Published: February 2011

Abstract
Background: The role of hypertension and/or antihypertensive medication use on bladder cancer risk is inconclusive. Given the high prevalence of hypertension in the United States, in the present study we investigated the relation between hypertension, antihypertensive drugs, and bladder cancer risk using a population-based case-control study conducted in Los Angeles County, California.
Methods: A population-based case-control study of bladder cancer was conducted in Los Angeles County from 1987-1999 and a total of 1586 age-, gender-, race- matched cases and neighborhood controls were included in the analyses. Participants were asked if they were told by a doctor that they had hypertension. They were also asked if they had taken any of the 21 brand names of diuretics and antihypertensive drugs listed in the questionnaire, which represented all the common prescription medications in these respective categories marketed in the US since the 1950s. Regular use was defined as taking a listed brand name drug two or more times a week for one month or longer. We asked regular users the ages at first and last use, duration of use, usual frequency and dosage of use, and the primary reason for such use.
Results: A history of hypertension was not related to bladder cancer; however, among hypertensive individuals, there was a significant difference in bladder cancer risk related to the use of diuretics or antihypertensive drugs (P for heterogeneity =0.003). Compared with individuals without hypertension, hypertensive individuals who regularly used diuretics/antihypertensives had a similar risk (odds ratio - OR, 1.05; 95% confidence interval − 95%CI, 0.86-1.29), while untreated hypertensive subjects had a 36% reduction in risk (OR, 0.64; 95% CI, 0.47-0.87). A greater reduction in bladder cancer risk was observed among current smokers (OR, 0.45; 95% CI, 0.28-0.72) and carriers of GSTM1 null (homozygous absence) genotypes (OR, 0.29; 95% CI, 0.16-0.54). Similarly, among smokers with GSTM1 null genotype, levels of 4-aminobiphenyl-hemoglobin adducts were significantly lower among untreated hypertensive individuals (45.7 pg/g Hb) compared to individuals without hypertension (79.8 pg/g Hb) (P = 0.009).
Conclusion: Our results suggest that untreated hypertension is associated with a reduced risk of bladder cancer, a finding that was partially supported by our biomarker data.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 860.
Abstract 862: Network patient navigation: An integrative, longitudinal model to reduce breast cancer disparities
Authors: Patierno Steven R. , LaVerda Nancy L. , Alexander Lisa M. , D. Ed , Levine Paul H. , Young Heather A. , Hoffman Heather J. 
Published: February 2011

Abstract
Introduction: Minority breast cancer mortality rates in Washington, DC are among the nation's highest. To address disparities we instituted the DC Citywide Patient Navigation Research Program (DC-PNRP) - an inter-institutional collaboration that is one of 9 National PNRP sites funded by NCI/ACS to evaluate the effectiveness of patient navigation in reducing barriers to obtaining health care while also addressing psychosocial factors.
Study Procedures: More than 1000 minority women have been enrolled from 7 recruitment sites at the point of suspicious finding to investigate whether patient navigation decreases time from suspicious breast finding to diagnostic resolution and time from diagnosis to treatment initiation. Utilizing a non-randomized design, concurrent, medical records-based controls have been identified. Data collection will extend through March 2010. A unique framework of “network navigation” emerged whereby services were integrated across a city-wide network of unaffiliated healthcare sites. Navigators from a broad partnership of clinical and community sites were trained to work collaboratively within a city-wide network to enroll patients in the study and assure each patient receives timely, quality care. This “integrative navigation” model is collecting data addressing not only structural barriers to access to care (i.e., inadequate insurance, lack of transportation, etc.), but also psychosocial barriers (i.e., fear, medical mistrust, acculturation, etc.). Frequent trainings, efforts that promote increased communication between navigators, and sharing of information about community resources were implemented to enhance care coordination and to assure appropriate referral strategies between community outreach, screening, and treatment sites.
Results and Conclusion: Implementation of DC-PNRP led us to broaden the original treatment-oriented navigation model to create a “Longitudinal Navigation” paradigm that follows the patient from outreach through survivorship. Data will be shown describing how this model addresses barriers to access and the underlying fragmentation of services that exist in DC for low-income uninsured or under-insured women. Data on the types and distribution of barriers will also be presented. This city-wide program serves as model for inter-institutional cooperation to improve health care access, particularly for the underserved.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 862.
Abstract 864: Correlates of mammography screening practice among immigrant women in Southern California
Authors: Shaheen Magda A. , Caro Blanca , Aman Yasser , Esfandiari Mahtash , Hulett Judie , Galal Osman 
Published: February 2011

Abstract
Introduction: Breast cancer (BC) is the most commonly diagnosed cancer among women in the United States. Immigrant underrepresented women are facing many challenges and barriers to knowledge, access to health care and preventive services. Few studies have examined factors associated with mammography screening among immigrant women in Southern California.
Purpose: We examined factors associated with mammography screening among immigrant women in Southern California.
Methods: A cross-sectional study of 517 immigrant women aged 40 years and older. The instrument included constructs from the Health Belief Model. The survey was conducted using a self administered questionnaire in the women's preferred language. The outcome variables were the percentage of women ages 40 and older who ever received a mammogram and the percentage of women who received a mammogram within the past year. Independent variables were demographics, frequency of visits to health care provider, and scores of the following variables: knowledge of BC symptoms and BC risk factors, perceived benefits, perceived health motivation and perceived barriers to obtaining a mammogram. We analyzed data using SPSS 15.
Results: of the 517 women, 50% were Iranian, 15% were Arab, and 21% were Asian/South Asian. Twenty eight percent had family history of BC, 63% had a friend diagnosed with BC, and 47% had yearly visit to the health care provider. Ever had a mammogram was reported by 88% of the women and 73% reported they had mammogram within the last 12 months. Participants had low knowledge of BC symptoms (mean score=7, Standard Deviation [SD]=3.5, range=1-13) and low knowledge of BC risk factors (mean score=8, SD=3.6, range=1-21). Women showed high health motivation (mean score=4.4, SD=0.6, range=1-5) and low barriers (mean score=2.4, SD=0.6, range=1-5). Predictors of ever had a mammogram were age, having a friend who was diagnosed with BC, and having a high score of health motivation. Factors associated with having a mammogram within the past year were having frequent visits to the health care provider, having a higher score in knowledge of BC symptoms, and having a lower score of perceived barriers to obtaining a mammogram.
Conclusions: The findings indicated that health care provider may influence the BC screening among immigrant women. There is a need for a culturally sensitive educational intervention to enhance the knowledge and awareness related to BC. This intervention can be provided through the health care provider and through the social support and family groups.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 864.